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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
“probiotic supplementation helps decrease pain and number of tender joints in adults with
rheumatoid arthritis?”
STUDY DESIGN: Review of three double-blind, randomized control trials published between
2008 and 2018. All studies were published in English in peer reviewed journals.
DATA SOURCES: Three double-blind, randomized control trials were found via PubMed.
OUTCOMES MEASURED: The outcomes measured included number of tender joints from
baseline to end of study counted by an investigator, visual analog scale (VAS) for pain severity,
and a Stanford Health Assessment Questionnaire visual analog scale (HAQ VAS) for pain
severity.
RESULTS: Two of the three articles found a statistically significant reduction in either patient
pain or number of tender joints. Alipour et al. found a mean statistical decrease in 0.72 tender
joints. Mandel et al. found a 19.8% decrease in patient pain compared to a 1.6% reduction in
pain in the placebo group. Zamani et al. found no statistically significant effect of probiotics on
patient pain.
CONCLUSION: There is conflicting evidence as to whether probiotic supplementation improves
pain and number of tender joints in adults with rheumatoid arthritis. Further research is needed to
determine the true effectiveness of probiotic supplementation on pain and number of tender
joints in patients with rheumatoid arthritis.
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INTRODUCTION
Rheumatoid Arthritis (RA) is a complicated autoimmune disease which causes systemic
inflammation, involving multiple joints throughout the body.1 This chronic disease leads to pain,
cartilage degradation, and deformities. Rheumatoid arthritis causes a wide array of extra-articular
complications such as pulmonary nodules, myocarditis and arrhythmias, renal failure, anemia,
and keratoconjunctivitis.2 Cardiovascular disease is a major cause of mortality in those with RA.2
RA is the most common autoimmune inflammatory arthritis, affecting nearly 1% of people
worldwide.3 If left untreated, RA can cause permeant disability and shorten one’s life expectancy
due to the many complications of the disease.3
It is estimated that treatment for articular and extra-articular complications of
rheumatoid arthritis costs the US about $19 billion each year.4 Although an exact cost of
treatment per year for each patient with RA is unknown, one study showed that Americans with
RA who are being treated with disease-modifying anti-rheumatic drugs (DMARDs), such as
methotrexate, incur about $19,000 in treatment cost per year.5 Those with RA are about 10 times
more likely to be on work disability compared to Americans without RA.6 An exact number of
health care visits per year for patients with RA is unknown; however, a study with 127 patients
showed a median of 7.2 office visits per year.7 Corticosteroids, such as prednisone, are typically
used to bridge a patient to DMARDs. 3 Corticosteroid injections, typically triamcinolone, can
provide relief if one or two joints are affected. Synthetic DMARDs are the cornerstone of
treatment, with methotrexate typically being first line, although leflunomide,
hydroxychloroquine (antimalarial), and tofacitinib can also be used.3 Biologic DMARDs such as
tumor necrosis factor (TNF) inhibitors like etanercept, infliximab, adalimumab and rituximab are
typically added to the treatment of those not responding to methotrexate.3
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Since no cure for rheumatoid arthritis has been found, alternative therapies should be
researched to bridge the gaps between current treatments. The cause of rheumatoid arthritis is
unknown, but studies have revealed that RA patients have altered gut microbiomes, suggesting
gut bacteria to be a possible etiology of RA and proposing that probiotic supplementation may
have a role in RA treatment.8 Probiotics restore the normal flora needed in our guts for healthy
digestion. Without this beneficial bacteria in our gut, pathogenic bacteria can overgrow and
cause inflammation within the body.1 Due to the relationship between gut microbiomes and RA,
probiotics are being proposed to help decrease rheumatoid arthritis symptoms as a supplemental
therapy along with DMARDs, corticosteroids, and TNFs. This paper evaluates three randomized
control trials (RCTs) comparing the efficacy of probiotic supplementation as an adjunctive
therapy for helping to decrease pain and the number of tender joints in RA.
OBJECTIVES
The objective of this selective EBM review is to determine whether or not “probiotic
supplementation helps decrease pain and number of tender joints in adults with rheumatoid
arthritis?”
METHODS
From searching on Pubmed with keywords “probiotics” and “rheumatoid arthritis”, three
randomized control trials (RCTs) were selected based on their credibility and relevance to my
question. Articles were considered credible if they were published in peer reviewed journals,
controlled bias through double-blinded randomization, and were reproducible studies. The
articles needed to measure patient-centered outcomes and be published within the past 10 years,
from January 2008 to January 2018. All three articles were published in English and in a peer
reviewed journal. Inclusion criteria comprised being double-blind, randomized control trials
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about adults with rheumatoid arthritis symptoms from 2008-2018. Articles were excluded from
this selective EBM if they included minors <18 years old and had patients without rheumatoid
arthritis. The summary of statistics reported were through p-values, mean difference from
baseline, and % change from baseline. In Table 1, the demographics and characteristics of the
three double blind RCTs can be found.
Articles were also selected based on meeting the criteria for population, interventions,
comparison groups, outcomes measured, and type of study. The population of studies targeted in
this selective EBM review were adult patients who had been diagnosed with rheumatoid arthritis.
The interventions used in each study were probiotic strains. Strains varied per study, but all are
considered probiotic supplementation. These probiotic caplets contained bacteria such as
Bacillus coagulans, L.casei and maltodexin, and a mixture of lactobacillus acidophilus,
lactobacillus casei , and Bifidobacterium. While the treatment groups received an oral probiotic
caplet, the placebo group received a visually similar oral placebo pill. The outcomes measured
that are discussed in this selective EBM include pain severity and number of tender joints.
Table1: Demographics & Characteristics of included studies
Study

Type

#pts

Age (yrs)

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Alipour,
2014
(8)

Double
blind
RCT

60

Between
20-80yrs

-Females with RA dx based on the
American College of
Rheumatology’s Criteria, for more
than 1 year who had inactive to
moderate levels and were under
treatment with DMARDs
-Not taking NSAIDs or cytokine
inhibitors

14

Capsule
containing 108
colony forming
units of L.casei
and maltodexin
taken once a day
for 8 weeks

Mandel,
2010,
(1)

Double
blind
RCT

45

Between
36-82 yrs

- Adult men & women with
symptoms of RA for at least 1 year
from outpatient departments of
Kashan University of Medical
Sciences

-Pregnant or lactating, under
hormone therapy, Dx of
DM, thyroid disorders,
kidney or hepatic diseases,
Cushing’s syndrome, IBD,
other inflammatory
disorders, digestive tract
diseases, lactose intolerance,
taking antioxidants,
vitamins, fiber, or omega-3
supplements 3 weeks prior
to interventions, using
antibiotics 1 month prior to
study, being on a weight
reduction diet, smoking or
being exposed to cigarette
smoke, using other probiotic
products
-Pregnancy
-Chronic IBD, kidney
disease, liver disease
-Exposure to > 10 mg/day of
prednisolone

1

Bacillus
coagulans GBI30, 6086 caplet
once a day for 60
days
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Zamani,
2016
(9)

Double
blind
RCT

60

Between
25-70

-Participants must have had 4 or
more of the following symptoms:
Morning stiffness lasting at least 1
hour (present for at least 6 weeks),
Soft tissue swelling in 3 or more joint
areas observed by physicians (present
for at least 6 weeks), Swelling of the
proximal interphalangeal,
metacarpophalangeal, or wrist joints,
Symmetric swelling(present for at
least 6 weeks), Rheumatoid nodules
(present for at least 6 weeks), The
presence of rheumatoid factor,
Radiographic erosions and/or
periarticular osteopenia in hand
and/or wrist joints
-Patients with RA that met the
American College of
Rheumatology’s criteria
-Were being treated out patiently
from Kashan University of Medical
Sciences from October 2015 to
December 2015
-Diagnosed with RA 6 months prior
with moderate and severe disease
activity (DAS-28 > 3.2)

-Treatment with other
probiotics

-Patients who had chronic
renal failure, renal tubular
acidosis, or pancreatitis
-Patients likely to be started
on biological agents
-Pregnant or lactating
women
-Patients unlikely to come
for follow up in 3 months
-Patients unable to read
numbers and/or unable to
mark the pain scale

8

Daily capsule
with freeze dried
strains of
lactobacillus
acidophilus (2 X
109 CFU/g) ,
lactobacillus
casei (2 X 109
CFU/g) , and
bifidobacterium
(2 X 109 CFU/g)
for 8 weeks

OUTCOMES
The outcomes measured in this selective EBM are the Stanford Health Assessment
Questionnaire Visual Analog Scale (HAQ VAS) pain scale for pain severity, visual analog scale
(VAS) pain scale for pain severity, as well as the number of tender joints from baseline to end of
study, which were counted by a rheumatologist.
RESULTS
This selective EBM review evaluates the effects of probiotic supplementation on the
effects of rheumatoid arthritis. All three RCTs were double blinded so that neither researchers
nor participants knew who received placebo or intervention. Two studies compared adult men
and women with RA while another study, Alipour et al., compared adult women with RA.3 Two
articles evaluate patient pain while the third article discusses number of tender joints. All three
articles study the effects of probiotic supplementation with other medications such as
methotrexate and DMARDS, instead of probiotics as a monotherapy.
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Alipour et al., assessed the number of tender joints from baseline to end of study, counted
by a rheumatologist. Sixty adult females, between the ages of 20 to 80, were recruited from a
rheumatology clinic associated with Sinai Hospital in Tabriz, Iran.8 The participants had meet
the American College of Rheumatology (ACR) criteria for more than 1 year and were currently
being treated with DMARDs.8 Patients could not be taking NSAIDs or cytokine inhibitors.8 The
intervention was a capsule containing 108 colony forming units of L.casei and maltodexin which
was taken once a day for 8 weeks.8 The placebo group received identical capsules containing
only maltodextrin taken once a day for 8 weeks.8 Adult females were randomly assigned to
intervention or placebo group, with twenty-four participants being assigned to the placebo group
and twenty-two in the intervention group. A capsule count was performed at the end of the study
which indicated that patients had followed the protocol and only took one pill a day for 8 weeks.8
Baselines characteristics, such as age, height, weight, BMI, menopausal status, education, and
current medications, showed no statistical significant difference between the placebo and
probiotic group.8 Of the 60 patients, 14 were noncompliant with the study protocol and therefore
not included in the final analysis.8
A Wilcoxon test was used to independently compare changes within the probiotic and
placebo group from baseline to end of study.8 An ANCOVA analysis was used to compare the
differences from baseline to end of study between the probiotic and placebo group.8 At the
conclusion of the study, the authors report a statistical mean difference of 0.72 joints ( 95% CI,
0.25 to 1.19) from baseline to end of study. The p-value for this measurement is 0.003 which was
reported as statistically significant.8 This result can be interpreted as the probiotic group had a
mean difference of 0.72 less tender joints than the placebo group. Although this p-value is
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statistically significant, it is important to note that 0.72 is not considered a reduction in 1 full
joint. The authors claim that no adverse effects were reported upon completion of the study.
Table 2. Effect of 8 weeks of probiotic supplementation on disease activity in females
with RA8
Study

Alipour (2014)

Mean difference

Confidence Interval

(95%)

(CI)

0.72

95% CI, 0.25 to 1.19

P-value

0.003

In a study by Mandel et al., 45 adult men and women between the ages of 36 to 82 were
randomized into intervention or placebo group.1 The participants, a majority of which were
women, had to have RA for at least one year and were recruited from the same practice.1 Those
in the probiotic group received Bacillus coagulans GBI-30, 6086 strain everyday for 60 days.
The intervention capsule contained green tea extract, methylsulfonylmethane, and vitamins and
minerals, as well as the probiotic itself.1 The placebo group received a matching pill, containing
microcrystalline cellulose, every day for 60 days.1 Twenty-two participants were analyzed in
each group. One participant was not analyzed due to starting an antibiotic for an upper
respiratory infection (URI) during the trial.1 Patients were seen at their primary investigator’s
office at baseline, 30 days, and 60 days.1 Participants were analyzed based on their improvement
from baseline to end of study from their pain scale reports which was measured through the
HAQ VAS pain scale.1 One patient discontinued treatment due to need for antibiotics for an
upper respiratory infection and was therefore not included in the final analysis.1
At the conclusion of the study, improvement of pain severity from baseline to end of
study was documented through the HAQ VAS pain scale with a p-value of 0.046 which was
statistically significant. The p-value was calculated using a Student t-test which measured the
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differences from baseline to end of study between the placebo and intervention group.1 It was
also noted that the intervention group had a reduction of 19.8% in patient pain from baseline to
end of study.1 Placebo group only had a 1.6% reduction in patient pain.1 It was determined that
the 19.8% reduction in patient pain was just shy of the ≥20% reduction needed by the American
College of Rheumatology (ACR) to meet ACR20 criteria.1 ACR20 criteria helps determine the
effectiveness of a therapy due to intervention compared to placebo and is defined as having a
≥20% improvement.

10

Although these results are statistically significant, it is hard to determine

if the improvement seen with Bacillus coagulans is based solely off the probiotic itself since
there were other elements in the intervention group’s capsule, such as vitamins.
The authors report no serious adverse effects although minor adverse events in the
intervention group, such as shingles, poison ivy, upper respiratory infection (URI), and leg
edema were documented.1 However, it was stipulated that these minor adverse events are
unlikely related to the probiotics. The placebo group also had documented minor adverse evenets
such as gastroesophageal reflux, URI, and urinary tract infection (UTI) which were also decided
to be unrelated by the investigator.1
Table 3. Reduction in patient pain from baseline to end of study1
Study

% change in patient

Confidence Interval

pain from baseline

(CI)

P-value

to end of study
Mandel (2010)

19.8% reduction

95% CI (0.01 to 0.91) 0.046

Zamani et al., randomly divided 60 study participants, recruited from an outpatient
practice, into intervention group or placebo group to determine the effects or probiotics on VAS
pain severity.9 Study participants were adult men and women with RA between the ages of 25-70
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years old.9 The visual analog scale for pain severity is a horizontal line 100 mm long that has
points along the line representing different intensities of pain such as no pain to unbearable
pain.11 The intervention group received probiotic capsules containing Lactobacillus acidophilus,
Lactobacillus casei, and Bifidobacterium while the placebo group received a visually
indistinguishable pill that contained starch instead of the probiotic strains.9 Participants took the
placebo or probiotic pill every day for 8 weeks.
Patients were assessed at baseline and at the end of the 8 week study and pain was
evaluated by the VAS pain scale. Eight patients withdrew from the study for personal reasons;
however, they were still included in the final analysis.9 At the conclusion of the study, it was
determined that the effects of probiotic supplementation on VAS pain were not significant. A
5mm difference was reported when comparing the change from baseline to end of study between
the placebo and probiotic group. The study concluded with a decrease in VAS pain of 16.7mm
for the probiotic group while the placebo group saw a decrease of 11.7mm. A repeated
ANOVA was used to compare the change in pain from baseline to end of study between the
probiotic group and placebo group.9 The repeated ANOVA produced a p-value of 0.25 which
was determined to not be statistically significant.9 A CI was not given. The study reports that no
side effects were encountered following probiotic supplementation.9
Table 4. Mean change from baseline to end of study for VAS pain9
Study

Zamani (2016)

DISCUSSION

Mean (± SD) change

Mean (± SD) for

for placebo group

probiotic group

-11.7 ±15.5

-16.7±18.1

P-value

0.25
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Rheumatoid arthritis is a systemic life long disease for which there is no cure, supporting
the need for new medications and supplements. Since there is evidence that those with RA have
altered gut microbiomes and impaired immune systems, the idea of probiotic supplementation in
these patients is a plausible one.1 According to the Food and Agriculture Organization of the
World Health Organization, probiotics can be beneficial to patients when given in correct
doses.12 Some studies suggest that probiotics, once ingested, can help fight the pathogens in the
gut that are responsible for intestinal inflammation.1 Probiotics, since classified as supplements,
do not need FDA approval before marketing.12 Manufacturers of probiotic supplements do,
however, have to notify the FDA before promoting their product. 12
Probiotics can be found in nearly all grocery and vitamin stores in the United States.
Probiotic supplements are not considered standard treatment for most diseases and therefore are
considered experimental and not covered by most commercial insurances. Some insurances may
cover probiotics if ordered by a healthcare professional, but the probiotics will likely not contain
the strength needed for those with autoimmune diseases. All this information considered,
probiotics are immensely cheaper than standard RA medications such as DMARDs.
The three randomized control trials in this review have conflicting results. Alipour et al.
supports probiotic supplementation; however, this result is not considered clinically significant
since it concluded an average decrease of less than one tender joint. While probiotics are fairly
inexpensive with a manageable dosing regime, the minor reduction observed in number of tender
joints does not justify regular dosing. However, for patients with advanced RA, the chance of a
small improvement in number of tender joints may make a difference in the quality of life for
these patients. It is important to note participants who violated protocol procedures were
excluded from this study’s analyses, making the results very precise. However, these results may
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not be feasible in real life as not every patient will not be fully compliant. If those 14 who
violated protocol had not been excluded in the analyses, the study may not have achieved
statistically significant evidence. Mandel et al., provides a statistically significant p-value for
patient pain, but this evidence does not meet ACR criteria by having less than a 20% reduction in
pain, making this study not clinically applicable. Zamani et al. shows no statistically significant
correlation between the use of probiotics and decrease in pain severity.9 All three of the studies
had limitations, mainly based off of sample size, length of study and compliance.
Although all articles studied adults with RA, their age intervals varied from 25-70, 36-82,
and 20-80.1,8,9. It is unknown if probiotics have more of an impact at specific ages. Alipour et al.
only discusses the effectiveness of probiotics on only adult females with RA, indicating less
generalizability to the US population.8 Although RA is more prevalent in women, Mandel et al.
showed a statistically significant reduction in patient pain in both men and women.1 All three
articles studied different strains of probiotic supplementation- Bacilllus Coagulans, L. Casei, and
Lactobacillus.1,8,9Alipour is the only article which doesn’t evaluate patient pain through VAS
and instead looks at tender joints.8 Two of the studies took place in Iran which may question the
applicability of the results to different patient populations in different countries. 8,9 The
intervention pill in Mandel et al. contained vitamins and green tea extract in addition to the
probiotic strain which may have confounded the results.1 Each of the three studies were
approximately 2 months in length.1,8,9 Mandel et al. stated that 60 days was long enough to
determine the effects of probiotics since NSAIDs relief can usually be determined within 60
days.1 Nevertheless, 60 days is not sufficient when monitoring disease involvement in a chronic
disease or the long term side effects of probiotics. 1,8,9
CONCLUSION
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There is conflicting information on whether probiotic supplementation improves pain and
number of tender joints in rheumatoid arthritis patients. Alipour et al. showed a statistically
significant average decrease in 0.72 tender joints with probiotic supplementation, however this is
not considered clinically significant as it is not a full joint. Mandel et al. concludes statistical
significance of probiotic supplementation on reduction in pain severity with a p-value of 0.046,
but a reduction in 19.8% pain does not meet ACR criteria and is therefore not clinically
significant. Zamani et al. showed no statistically significant effect on patient pain.
To determine a more concrete answer to whether probiotics have a significant effect on
rheumatoid arthritis symptoms, there needs to be studies with increased sample sizes and for a
period of time longer than two months.1,8,9 Rheumatoid arthritis is a chronic disease that patients
suffer with for years and with studies only conducted for two months, it is difficult to determine
the long term efficacy of probiotic supplementation as well as any long term side effects. An
ongoing study over a year or more should be conducted. Each of the three articles in this review
used different strains of probiotics. A study with multiple intervention groups, comparing the
effectiveness of different strains of probiotic groups to each other and a placebo group could
provide even more information. It is also important to note that each of the three studies took
places overseas so future studies should be conducted in different countries around the world to
determine the generalizability of the treatment effects to the global population. Future studies
should also compare the effects of probiotic supplementation on women with RA to men with
RA to determine if there are any differences between genders.
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